Editorial
doi: 10.1016/S1081-1206(10)61277-X.
Cross-reactivity of cyclooxygenase 2 inhibitors in patients with a history of cutaneous reactions to cyclooxygenase 1 inhibitors
- PMID: 15702807
- DOI: 10.1016/S1081-1206(10)61277-X
Item in Clipboard
Editorial
Cross-reactivity of cyclooxygenase 2 inhibitors in patients with a history of cutaneous reactions to cyclooxygenase 1 inhibitors
Ann Allergy Asthma Immunol.
2005 Jan.
No abstract available
Comment on
-
Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.Ann Allergy Asthma Immunol. 2004 Oct;93(4):360-4. doi: 10.1016/s1081-1206(10)61395-6. Ann Allergy Asthma Immunol. 2004. PMID: 15521372 Clinical Trial.
-
Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.Ann Allergy Asthma Immunol. 2005 Jan;94(1):29-33. doi: 10.1016/S1081-1206(10)61281-1. Ann Allergy Asthma Immunol. 2005. PMID: 15702812
-
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.Ann Allergy Asthma Immunol. 2005 Jan;94(1):34-8. doi: 10.1016/S1081-1206(10)61282-3. Ann Allergy Asthma Immunol. 2005. PMID: 15702813 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
